AAlzheimer disease
First line
Alzheimer disease
First line
First-line for mild-to-severe Alzheimer's disease ( NG97, 2018). Starting dose 5 mg once daily at bedtime; uptitrate to 10 mg after 4–6 weeks. For severe disease a 23 mg dose is available in the US, while the EU continues 10 mg. The 2018 Cochrane meta-analysis showed cognitive improvement (ADAS-Cog) by 2.9 points and functional gains. The effect is symptomatic and does not modify progression.
Sources
ICD-10: G30 · ICD-11: 8A20